Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2022.571 | A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-02: Patients With Disease Progression After Receiving Systemic Treatment for Non-Small-Cell Lung Cancer (NSCLC) |
Dr. LI Molly Siu Ching 李兆澄醫生 |
| 2023.149 | A Phase II, Open-label, Single-arm, Multi-centre Study to Evaluate the Safety and Efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (OSTARA) |
Dr. LI Molly Siu Ching 李兆澄 醫生 |
| 2026.109 | Tarlatamab in Combination with Osimertinib for Small Cell-transformed EGFR-mutated NSCLC (TOSCE) | Dr. Li Molly Siu Ching |
| 2026.240 | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER | Dr. Li Molly Siu Ching |
| 2026.493 | A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of MK- 2010 in Combination with Sacituzumab Tirumotecan (Sac-TMT) in Participants with Advanced Solid Tumors | Dr. Li Molly Siu Ching |
| 2025.505 | RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC | Dr. LI Molly Siu Ching |
| 2024.230 | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | Dr. LI Molly Siu Ching |
| 2024.064 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306) | Dr. LI Molly Siu Ching |
| 2024.271 | A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301) | Dr. LI Molly Siu Ching |
| 2024.636 | A Phase 1/2 Open-Label, Multicenter, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA) | Dr. LI Molly Siu Ching |
| 2025.459 | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON−SMALL CELL LUNG CANCER | Dr. LI Molly Siu Ching |
| 2026.036 | A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies | Dr. LI Molly Siu Ching |
| 2023.642 | A prospective study on artificial intelligence guided lung cancer screening for high-risk never smokers in Hong Kong | Dr. LI Molly Siu Ching |
| 2025.302 | A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15) | Dr. LI Molly Siu Ching |
| 2025.366 | A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | Dr. LI Molly Siu Ching |
| 2024.456 | A Phase 2, Open-Label, Single-Arm Study of Amivantamab and Lazertinib Combination Therapy as First-Line Treatment in Patients with EGFR-Mutated Recurrent Non-Small Cell Lung Cancer after Previous Treatment with Adjuvant Osimertinib in Early-Stage Disease | Dr. LI Molly Siu Ching |
| 2023.649 | A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB COMPARED WITH PLACEBO PLUS ATEZOLIZUMAB IN PARTICIPANTS WITH COMPLETELY RESECTED STAGE IIB, IIIA, OR SELECT IIIB, PD-L1 POSITIVE, NON-SMALL CELL LUNG CANCER WHO HAVE RECEIVED ADJUVANT PLATINUM-BASED CHEMOTHERAPY | Dr. LI Molly Siu Ching |
| 2023.654 | An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations | Dr. LI Molly Siu Ching |
| 2024.171 | A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | Dr. LI Molly Siu Ching |
| 2024.174 | A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic Non–Small-Cell Lung Cancer (mNSCLC) | Dr. LI Molly Siu Ching |
| 2024.183 | A Phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression | Dr. LI Molly Siu Ching |
| 2019.514 | EBBI, the key to excellent functional outcome in Chinese paediatric patients with lower extremity bone sarcoma | Dr . LI Moses Man Lung |
| 2011.051 | Evaluation of Quality of Care – Haemodialysis Public-Private-Partnership, HA | Prof. LI Philip |
| 2016.672 | Developing Gistful Thinking and Cognitive Flexibility among High-Functioning Adolescents with Autism Spectrum Disorder |
Mr. LI Philip Hung Kong 李鴻鋼 |
| 2009.057 | The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy | Prof. Li Philip Kam Tao |
| 2010.015 | Management of Diabetes Patients in a Primary CARE Setting - Health-Related Quality of Life and Anxiety Scores | Professor Li Philip Kam-tao |
| 2026.390 | A Cross-Sectional Analysis of the Association Between MASLD Severity and Categories of CAD Severity | Dr. LI Po Yi |
| 2017.410 | The experience of patients and family caregivers in managing pneumoconiosis in the family context: An exploratory qualitative study | Prof. LI Polly Wai Chi |
| 2017.595 | Promoting brain health among people with suboptimal cognitive functioning in Hong Kong: A Brain Vitality Enhancement (BRAVE) program | Prof. LI Polly Wai Chi |
| 2018.430 | Psychometric evaluation of the Chinese version of the Atrial Fibrillation Effect on QualiTy-of-Life questionnaire and the Atrial Fibrillation Knowledge Scale | Prof. LI Polly Wai Chi |
| 2019.086 | The effects of an empowerment-based cognitive behavioural therapy for insomnia on sleep, cognitive function and health-related quality of life in persons with mild cognitive impairment: A waitlist randomized controlled trial | Prof. LI Polly Wai Chi |
| 2016.419 | Low back pain self-management: evaluation of an intensive in-patient low back pain education program for female elderly with low back pain: A cohort study |
Miss LI Pui Man 李佩雯 |
| 2024.084 | Validation of the Chinese Fall Efficacy Scale (FES) | Ms. LI Pui Man |
| 2009.468 | Effect of a modified Tai Chi exercise on quality of life, anxiety and deprssion among stroke patients: a quasi-experimental study | Mr. Li Pui On |
| 2016.546 | Eye-hand Coordination, Visual Attention, and Physical Activity in Children with Cerebral Palsy |
Miss LI Ru 李如 |
| 2026.434 | Development of a food-based dietary inflammatory index and a pilot randomized controlled trial of anti-inflammatory dietary intervention for sarcopenic obesity in older adults |
Dr. LI Shuyi 黎淑儀 |
| 2023.590 | A randomized controlled trial of an acceptance and commitment therapy-based parenting program for improving parenting stress and other health outcomes of parents and children with autism spectrum disorder |
Miss. LI Sini 李斯妮 |
| 2026.108 | KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations | Dr. LI Siu Ching |
| 2025.339 | Lung Cancer Biomarker: Methylation Risk Score for Early Detection and Minimal Residual Disease Monitoring | Dr. LI Siu Ching |
| 2025.626 | A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion | Dr. LI Siu Ching |
| 2026.083 | Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy | Dr. Li Siu Ching |
| 2025.808 | ATOM2: A randomized phase II trial on Ablative Therapy to Oligoresidual Metastasis in EGFR mutated non-small cell lung cancer after Osimertinib treatment | Dr. LI Siu Ching |
| 2026.125 | A GLOBAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FIRMONERTINIB COMPARED WITH INVESTIGATOR’S CHOICE OF OSIMERTINIB OR AFATINIB AS FIRST-LINE TREATMENT IN PARTICIPANTS WHO HAVE LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR P-LOOP AND ALPHA C-HELIX COMPRESSING (PACC) UNCOMMON MUTATIONS (ALPACCA) | Dr. Li Siu Ching |
| 2024.722 | Artificial intelligence as first-reader for lung cancer screening in high-risk non-smokers: a diagnostic validation study | Dr. LI Siu Ching |
| 2023.101 | Effect of IL24-expressing mesenchymal stem cells on immune system in lung cancer patients and health donors |
Dr. LI Siu Ching 李兆澄 |
| 2022.364 | Investigating the genomic landscape and evolution and its impact on clinical outcome in ALK-positive non-small cell lung cancer |
Dr. LI Siu Ching 李兆澄 |
| 2023.099 | Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer: an open-label, multicenter, single arm phase 2 study |
Dr. LI Siu Ching 李兆澄 |
| 2022.236 | Evaluation of Immune Tumour Microenvironment of EGFR mutation positive NSCLC after Osimertinib treatment |
Dr. LI Siu Ching 李兆澄 |
| 2022.253 | Establishment of New Territories East Cluster Lung Cancer Database |
Dr. LI Siu Ching 李兆澄 |
| 2026.184 | ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy. | Dr. LI Siu Ching |
Page 161 of 288.